Close Menu

Until last week, the merger between Oxford GlycoSciences and Cambridge Antibody Technology, announced on Jan. 23, seemed like a done deal. Sure, shareholders from both parties, as well as the court, still needed to approve it. But both representatives of both companies and experts said that the couple was well-situated with a comfortable cushion of shared cash, and matched in terms of its technologies: OGS’s proteomics capabilities and CAT’s antibody knowledge, they agreed, would go together well.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The chief executive of the National Health Service in England is to call for tumor-agnostic drugs to be "fast-tracked," according to the Times.

Researchers in Australia are sequencing the Wollemi pine tree to try to protect it from extinction, Australia's ABC News reports.

Computerworld ranks Illumina as one of the top midsize organizations to work at in IT.

In Genome Research this week: links between biological aging and mutations affecting epigenetic regulators; long-read sequencing-based strategy to map chromatin accessibility; and more.